Navigation Links
TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
Date:5/18/2008

-- Additional Data Demonstrated Higher Overall Maintenance of Healed

Erosive Esophagitis and Symptom Relief versus Placebo --

SAN DIEGO, May 18 /PRNewswire/ -- TAP Pharmaceutical Products Inc. today reported results from three pivotal Phase 3 studies evaluating investigational new drug TAK-390MR, the first proton pump inhibitor (PPI) with an innovative dual delayed release technology, in healing patients with erosive esophagitis (EE) and in maintenance of healed EE. The data were presented at the Digestive Disease Week (DDW) annual meeting in San Diego.

"The innovative dual delayed release technology delivers TAK-390MR in two separate releases, which is a first in the PPI class and makes TAK-390MR a very interesting potential future treatment option," said Dr. David Peura, professor of medicine, University of Virginia Health System, past president of the American Gastroenterological Association.

Data from the two separate EE healing studies demonstrated that patients treated with TAK-390MR 60 mg and 90 mg experienced higher overall healing after eight weeks, versus patients taking lansoprazole 30 mg. In addition, data from a six-month maintenance of healed EE study demonstrated that patients treated with TAK-390MR 30 mg and 60 mg experienced statistically significant overall maintenance and symptom relief over placebo.

Healing of Erosive Esophagitis Studies

TAK-390MR was compared to lansoprazole in two identically designed, double-blind, randomized, controlled trials in patients with confirmed EE. A total of 4,092 patients were enrolled in the two global studies. The primary objective was to evaluate overall healing rates over eight weeks after once-daily administration of TAK-390MR 60 mg or 90 mg or lansoprazole 30 mg. The results for each study were analyzed using life table and crude rate methods.

Results from these trials demonstrated that TAK-390MR 60 mg and 90 mg produced consistently high healing ra
'/>"/>

SOURCE TAP Pharmaceutical Products Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Oct. 30, 2014   NxStage® Kidney Care, Inc ., ... ), is proud to host the grand opening ceremony of ... 1600 W. 16 th Street on November 20, 2014 ... highly trained medical staff who are committed to providing patients ... life benefits made possible through more flexible dialysis treatment options.   ...
(Date:10/30/2014)... Oct. 30, 2014  Electronic health records uptake ... result of government initiatives and the considerable resources ... have invested over the past five years. Electronic ... IT, and U.S. clinicians use them on a ... http://photos.prnewswire.com/prnh/20141029/155278LOGO Frost & Sullivan,s ...
(Date:10/30/2014)... , Oct. 30, 2014  Nektar Therapeutics (Nasdaq: ... for the third quarter ended September 30, 2014 on ... financial markets. Howard Robin , president and chief ... the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 ... release and a live audio-only Webcast of the conference ...
Breaking Medicine Technology:Grand Opening of NxStage Kidney Care Oak Brook IL Center 2Grand Opening of NxStage Kidney Care Oak Brook IL Center 3Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2
... WESTON, Fla., Oct. 8 American Scientific Resources Inc. (PINK ... for the periods ending December 31, 2007 and December 31, ... www.Pinksheets.com . ... , is a leading provider of innovative next-generation, health, medical, ...
... , ALEXANDRIA, Va., Oct. 8 The Health Industry ... campaign focused on educating key audiences about the value ... of patient procedures are supported by medical products delivered ... role distributors play in supporting healthcare and making it ...
Cached Medicine Technology:American Scientific Resources Inc. Discloses Audited Financials for 2007 and 2008 2
(Date:10/30/2014)... her research group at the DFG Research Center for ... TU Dresden (CRTD) demonstrated for the first time the ... in three dimensions from mouse embryonic stem cells. Correct ... along the dorsal/ventral axis was observed., This study has ... Stem Cell Reports " on 30.10.2014 ., For many ...
(Date:10/30/2014)... 30, 2014 Timothy, InstaKNOT’s ... Beach firefighters, showing that you are never too young ... met firefighters Tracey and Carl at the 2013 Santa ... the Pompano Beach Chamber of Commerce. Tracey gave Timothy ... letting Timothy wear his real fireman’s hat, and extending ...
(Date:10/30/2014)... Calif. (PRWEB) October 30, 2014 ... mutually exclusive concepts in the medical-grade skin care ... the development of uniquely potent topical dermatological products, ... System ( http://www.RefinitySkinScience.com ) with patented COSMEDERM®-7 anti-irritant ... glycolic acid concentrations (50% and 70%) and a ...
(Date:10/30/2014)... 30, 2014 Paramount Rx, a full-service ... increasing efforts to help people save money through its ... increase for prescription drugs in the new health care ... resources to bridge the relationship between consumers, businesses and ... biggest challenges people face today with medical costs is ...
(Date:10/30/2014)... Tara Haelle HealthDay ... -- More than 100 genes have been identified that ... report. And researchers say they are on their ... may contribute to the disorder. Autism spectrum disorders ... and social difficulties and repetitive behaviors. An estimated one ...
Breaking Medicine News(10 mins):Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 3Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 4Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3
... Insurance Coverage Exclusions for Preexisting Conditions WASHINGTON, March ... -- a national, non-profit organization dedicated to the ... to health care through public policy reform at ... Senator Jay Rockefeller (D-WV) and Representative Joe Courtney ...
... Renaissance Laser and Vein Institute, the industry-leading ... patients. The Renaissance Laser and Vein Institute ... plastic and reconstructive surgery.In a faltering economy, many ... pricey beauty rituals to save money. Though this ...
... campaign goalFAIRFAX, Va., March 17 The newly formed ... million as part of its initial campaign goal and ... goal. This includes a recent pledge of $1 million ... high precision radiation therapy treatments for cancer and other ...
... Story" is a riveting 60-second spot depicting a biomedical ... March 17 The Foundation for Biomedical Research (FBR) ... Story." The 60-second spot introduces viewers to a ... cancer research, and is now herself battling this disease ...
... likely to be infected, study finds , , TUESDAY, March 17 ... help decrease the spread of tuberculosis in hospitals, researchers suggest. ... to air from patient rooms in a hospital in Lima, ... The study found that 35 percent of guinea pigs exposed ...
... April 19 SALT LAKE CITY, March 17 Within ... for trained IT professionals who understand healthcare. Western ... established to address workforce needs by offering relevant, accessible ... meet that need by offering a B.S. in ...
Cached Medicine News:Health News:National Patient Advocate Foundation Hails Senator Rockefeller, Representative Courtney for Introducing Preexisting Conditions Bill, Ensuring Patient Access to Health Coverage 2Health News:Renaissance Laser and Vein Clinic (laserandveinclinic.com) Provides Clients with Affordable Varicose Vein Removal Treatment 2Health News:Radiation Oncology Institute (ROI) Campaign Raises $7 Million 2Health News:Foundation for Biomedical Research Releases Groundbreaking PSA 2Health News:Western Governors University Addresses Rising Demand for Healthcare IT Professionals with B.S. in Health Informatics 2Health News:Western Governors University Addresses Rising Demand for Healthcare IT Professionals with B.S. in Health Informatics 3
... procedures are now greatly improved with Volk's ... new lens promotes precise and focused laser ... optimized for enhanced viewing and laser treatment ... design comes standard with LaserWindow for optimal ...
... Super Macula® 2.2 offers extremely high resolution ... while achieving an exceptionally wide 78° field ... choice for critical evaluation of the optic ... detailed views of the macula and disc. ...
... Volk Area Centralis® is excellent for ... and changes from macular degeneration, retinal ... diabetic retinopathy and other retinal conditions. ... treatment of these conditions providing excellent ...
... The original 130° QuadrAspheric lens has ... 1989 as the preferred wide field fundus ... provides a definite advantage over competitive wide ... displacement, and ease of use. This lens ...
Medicine Products: